Vivoryon Therapeutics « Terug naar discussie overzicht

quote:

DeZwarteRidder schreef op 4 maart 2024 09:39:

[...]
Je zit er dus helemaal naast.

quote:

DeZwarteRidder schreef op 30 juli 2023 15:23:

[...]
Dat ziet er slecht voor Vivo en de patiënten:

From March 2015 to April 2017, the Phase 2 SAPHIR trial compared a 12-week course of twice-daily 800 mg PQ912 tablets to placebo. It enrolled 120 people with MCI or mild dementia due to AD as ascertained by CSF Aß levels at screening. This trial took place in seven European countries. It met its primary outcome of safety, with no difference in the frequency of adverse events between the treatment and placebo arms. The treatment group had more skin reactions and gastrointestinal problems than placebo, and more discontinuations. PQ912 inhibited QC activity in CSF by 92 percent. It appeared to slightly decrease pyroglutamate Aß oligomers in CSF, though CSF Aß oligomers' concentrations are near the assay’s detection limit. The treatment group showed a benefit on working memory and a trend on attention, but no difference on five other neuropsychological tests. On EEG readings, the treatment group showed a reversal of AD-induced changes in theta and alpha rhythms. In CSF, the synaptic marker neurogranin and the inflammatory marker YKL40 trended downward from a known rise in AD. CSF AD biomarkers were unchanged (Jun 2017 news; Scheltens et al., 2018; Briels et al., 2020).

quote:

lucas D schreef op 20 november 2023 13:19:

Bij goedkeuring Alzheimer medicijn word
Vivoryon een > € 100,00 aandeel.